Board member Dr. Brian Kotzin resigns from Rigel board effective Sept. 16, 2024

RIGEL PHARMACEUTICALS INC

Dr. Brian Kotzin resigned as independent director and from all committees, effective September 16, 2024.
Resignation not due to any disagreement with Rigel's operations, policies, or practices.
Kotzin chaired the Scientific and Clinical Trial Advisory Committee and served on the Corporate Governance, Healthcare Compliance, and Nominating committees.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian Kotzin

Director

RIGL · RIGEL PHARMACEUTICALS INC

Effective: 2024-09-16
Filed: September 19, 2024, 7:59 PM ET

On September 16, 2024, Dr. Brian Kotzin notified Rigel Pharmaceuticals, Inc. (“ Rigel ”) of his decision to resign as a member of the Board of Directors of Rigel (the “ Board ”) and from the committees on which he serves, effective September 16, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Brian Kotzin resigned as Director at RIGEL PHARMACEUTICALS INC.

Action: resigned
Role: Director

Exact text from the filing

On September 16, 2024, Dr. Brian Kotzin notified Rigel Pharmaceuticals, Inc. (“ Rigel ”) of his decision to resign as a member of the Board of Directors of Rigel (the “ Board ”) and from the committees on which he serves, effective September 16, 2024.

View on SEC.gov

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-101327

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.